Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Failure of Warfarin Anticoagulation Therapy after Administration of Oral Terbinafine

I. Štětkářová, J. Čupáková

. 2021 ; 64 (2) : 132-135. [pub] 20210730

Jazyk angličtina Země Česko

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21028048

Grantová podpora
PROGRES Q 35 Univerzita Karlova v Praze
UNCE/MED/002 Univerzita Karlova v Praze

Warfarin is widely used anticoagulant drug for a variety of diseases (thromboembolic disease, atrial fibrillation, etc.). It has three most important parallel metabolic pathways, CYP1A2, CYP3A4 and CYP2C9. Terbinafine is a potent CYP2D6 inhibitor. A possible drug interaction could lead to an increased pharmacological effect of the above drugs. Enzyme induction with CYP3A4, CYP2C9, CYP1A2 inducers may have occurred. Case report: We present a case report of an 88-year-old male patient who has been successfully anticoagulated with warfarin due to atrial fibrillation. He was orally administered terbinafine to treat onychomycosis. Two weeks after initiation of this drug the patient experienced dizziness and feelings of instability, for which he was admitted to the neurology department. A low-efficient INR level was found at the baseline, presumably due to warfarin interaction with terbinafine. The induction of liver enzymes lasts 10-14 days, which matches the introduction of the antifungal agent. Conclusion: Combined therapy with warfarin and oral terbinafine is actually rarely prescribed but, if used, their interaction can have serious consequences in many clinical situations for which anticoagulation therapy with warfarin is indicated.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21028048
003      
CZ-PrNML
005      
20211129142828.0
007      
ta
008      
211105s2021 xr a f 000 0|eng||
009      
AR
024    7_
$a 10.14712/18059694.2021.23 $2 doi
035    __
$a (PubMed)34331435
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Štětkářová, Ivana, $d 1963- $7 xx0030376 $u Department of Neurology, Third Faculty of Medicine, Charles University and Faculty Hospital Královské Vinohrady, Prague, Czech Republic
245    10
$a Failure of Warfarin Anticoagulation Therapy after Administration of Oral Terbinafine / $c I. Štětkářová, J. Čupáková
504    __
$a Literatura
520    9_
$a Warfarin is widely used anticoagulant drug for a variety of diseases (thromboembolic disease, atrial fibrillation, etc.). It has three most important parallel metabolic pathways, CYP1A2, CYP3A4 and CYP2C9. Terbinafine is a potent CYP2D6 inhibitor. A possible drug interaction could lead to an increased pharmacological effect of the above drugs. Enzyme induction with CYP3A4, CYP2C9, CYP1A2 inducers may have occurred. Case report: We present a case report of an 88-year-old male patient who has been successfully anticoagulated with warfarin due to atrial fibrillation. He was orally administered terbinafine to treat onychomycosis. Two weeks after initiation of this drug the patient experienced dizziness and feelings of instability, for which he was admitted to the neurology department. A low-efficient INR level was found at the baseline, presumably due to warfarin interaction with terbinafine. The induction of liver enzymes lasts 10-14 days, which matches the introduction of the antifungal agent. Conclusion: Combined therapy with warfarin and oral terbinafine is actually rarely prescribed but, if used, their interaction can have serious consequences in many clinical situations for which anticoagulation therapy with warfarin is indicated.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $7 D000925
650    _2
$a antifungální látky $x aplikace a dávkování $x škodlivé účinky $7 D000935
650    _2
$a fibrilace síní $x farmakoterapie $7 D001281
650    12
$a lékové interakce $7 D004347
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a onychomykóza $x farmakoterapie $7 D014009
650    _2
$a terbinafin $x aplikace a dávkování $x škodlivé účinky $7 D000077291
650    _2
$a warfarin $x aplikace a dávkování $x škodlivé účinky $7 D014859
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Čupáková, Jitka $7 xx0151102 $u Pharmacy Department, Faculty Hospital Královské Vinohrady, Prague, Czech Republic
773    0_
$w MED00010947 $t Acta Medica (Hradec Kralove) $x 1805-9694 $g Roč. 64, č. 2 (2021), s. 132-135
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34331435 $y Pubmed
910    __
$a ABA008 $b A 3077 $c 1072 $y p $z 0
990    __
$a 20211105 $b ABA008
991    __
$a 20211118111712 $b ABA008
999    __
$a ok $b bmc $g 1728692 $s 1148593
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 64 $c 2 $d 132-135 $e 20210730 $i 1805-9694 $m Acta Medica $n Acta Med. (Hradec Král.) $x MED00010947
GRA    __
$a PROGRES Q 35 $p Univerzita Karlova v Praze
GRA    __
$a UNCE/MED/002 $p Univerzita Karlova v Praze
LZP    __
$b NLK118 $a Pubmed-20211105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...